Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 63 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
Injeck Pharma from Wavre, company number BE0689594279, closed financial year 2025 with a result of € 59,891 after tax. For that financial year Injeck Pharma recorded a gross margin of € 100,110 and equity of € 20,094. Compared with financial year 2024, the result moved from € 53,684 to € 59,891. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on May 13, 2026.
€ 20,094
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 59,891
▲ 12% vs 2024
Profit after tax over the fiscal year.
€ 39,656
▲ 174% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 59,800 paid out
100 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 61,269
▼ 21% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 83,809
▼ 11% vs 2024
€ 18,114 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.
€ 93
▼ 85% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 5,591
▼ 13% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 44,343 | € 64,042 | € 83,037 | € 100,110 | ▲ 21% |
| Profit after taxes | € 31,134 | € 45,900 | € 53,684 | € 59,891 | ▲ 12% |
| Equity | € 24,370 | € 20,270 | € 20,003 | € 20,094 | |
| Total debts | € 61,202 | € 108,447 | € 170,047 | € 165,337 | ▼ 3% |
| Cash | € 21,784 | € 27,021 | € 14,465 | € 39,656 | ▲ 174% |
| Land & buildings | € 11,711 | € 20,431 | € 27,810 | € 26,437 | ▼ 5% |
| Retained profit | € 4,370 | € 270 | € 3 | € 94 | ▲ € 91 |
| Dividend | € 35,294 | € 50,000 | € 53,950 | € 59,800 | ▲ 11% |
| Bank debt | € 19,354 | € 33,227 | € 94,166 | € 83,809 | ▼ 11% |
| Balance sheet total | € 85,571 | € 128,716 | € 190,051 | € 185,431 | ▼ 2% |
Key figures of Injeck Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Injeck Pharma?
What happened at Injeck Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 59,891 (▲ 12% vs 2024). Source: NBB ↗
- Thomas Jecker became a director. NBB
- New establishment in Wavre. KBO
- Start of the company according to the CBE. KBO
In short
From € 31,134 profit in 2022 to € 59,891 profit in 2025.
Paid € 53,542 in corporate taxes since 2022.
Best year ever: 2025, with € 59,891 profit.
Paid out € 199,044 in dividends to the owners in total.
A new publication or filing at Injeck Pharma? We notify you, reason included.
Follow Injeck PharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Directors
According to the 2025 annual accounts
Thomas Jecker
Director
since 2023
Establishments
Establishment units
Physical locations of this company
Montagne d'Aisemont 75 box 2
1300 Wavre
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0689.594.279
- VAT number
- BE 0689.594.279
- Registered office
- Montagne d'Aisemont 75 bus 2, 1300 Wavre
- Names & denominations
- Injeck Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 31 January 2018
- Peppol
- Active · Active since 14 Oct 2025
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Administratieve en ondersteunende activiteiten ten behoeve van kantoren
Activiteiten van ingenieurs en aanverwante technische adviseurs, exclusief landmeters-experts
Diverse administratieve activiteiten ten behoeve van kantoren